SG Americas Securities LLC decreased its holdings in Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) by 33.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,161 shares of the medical research company’s stock after selling 3,583 shares during the period. SG Americas Securities LLC’s holdings in Quest Diagnostics were worth $980,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of the stock. Mystic Asset Management Inc. bought a new position in shares of Quest Diagnostics in the 4th quarter worth $25,000. Wagner Wealth Management LLC bought a new position in Quest Diagnostics in the fourth quarter worth about $35,000. Anfield Capital Management LLC raised its holdings in Quest Diagnostics by 1,077.8% in the fourth quarter. Anfield Capital Management LLC now owns 212 shares of the medical research company’s stock worth $37,000 after purchasing an additional 194 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. purchased a new stake in shares of Quest Diagnostics during the fourth quarter valued at about $38,000. Finally, NuWave Investment Management LLC bought a new stake in shares of Quest Diagnostics in the 1st quarter valued at about $40,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.
Analyst Ratings Changes
DGX has been the subject of a number of analyst reports. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, July 7th. Citigroup downgraded Quest Diagnostics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $175.00 to $140.00 in a research note on Monday, April 4th. Bank of America decreased their price target on Quest Diagnostics from $166.00 to $163.00 and set a “buy” rating for the company in a research note on Friday, April 22nd. Mizuho dropped their price target on Quest Diagnostics from $185.00 to $160.00 and set a “maintains” rating on the stock in a research note on Friday, July 22nd. Finally, UBS Group increased their price objective on shares of Quest Diagnostics from $139.00 to $150.00 in a research report on Sunday, April 24th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $149.25.
Quest Diagnostics Stock Up 1.0 %
Quest Diagnostics (NYSE:DGX – Get Rating) last posted its quarterly earnings results on Thursday, July 21st. The medical research company reported $2.36 EPS for the quarter, beating the consensus estimate of $2.26 by $0.10. The company had revenue of $2.45 billion for the quarter, compared to analyst estimates of $2.34 billion. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The firm’s revenue was down 3.8% on a year-over-year basis. During the same period in the prior year, the company earned $3.18 earnings per share. As a group, equities research analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.
Quest Diagnostics Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 20th. Shareholders of record on Wednesday, July 6th were given a $0.66 dividend. The ex-dividend date was Tuesday, July 5th. This represents a $2.64 annualized dividend and a yield of 1.93%. Quest Diagnostics’s dividend payout ratio is presently 21.96%.
Insider Transactions at Quest Diagnostics
In related news, Director Timothy M. Ring sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $133.47, for a total value of $266,940.00. Following the completion of the transaction, the director now directly owns 23,933 shares in the company, valued at approximately $3,194,337.51. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Stephen H. Rusckowski sold 282,408 shares of the company’s stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $140.12, for a total transaction of $39,571,008.96. Following the completion of the transaction, the chief executive officer now directly owns 334,833 shares of the company’s stock, valued at approximately $46,916,799.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Timothy M. Ring sold 2,000 shares of Quest Diagnostics stock in a transaction on Friday, July 1st. The shares were sold at an average price of $133.47, for a total transaction of $266,940.00. Following the completion of the sale, the director now directly owns 23,933 shares in the company, valued at approximately $3,194,337.51. The disclosure for this sale can be found here. Insiders have sold 335,012 shares of company stock valued at $46,920,991 in the last 90 days. 1.70% of the stock is currently owned by company insiders.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
- Get a free copy of the StockNews.com research report on Quest Diagnostics (DGX)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter’s Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.